Mexico Cannabis Legalization: Status, Timeline & Legal Framework

Executive Summary

Mexico's cannabis legalization journey represents one of the most complex and protracted policy debates in Latin America, spanning more than a decade of Supreme Court rulings, legislative deadlines, and regulatory uncertainty. Despite the Supreme Court of Justice of the Nation (SCJN) declaring cannabis prohibition unconstitutional in 2018 and ordering Congress to enact comprehensive reform, Mexico still operates without a fully functional legal framework for adult-use cannabis as of September 2026. The recent SCJN ruling allowing cannabis-infused foods for personal consumption marks another incremental judicial expansion of rights in the absence of legislative action. This piecemeal approach has created a legal gray zone where personal cultivation and consumption enjoy constitutional protection, but commercial production, distribution, and retail sales remain prohibited. The impasse affects an estimated 127 million Mexican citizens, billions of dollars in potential tax revenue, and the operational strategies of multinational cannabis companies eyeing Latin America's second-largest economy. For patients, advocates, and investors, understanding Mexico's fragmented regulatory landscape requires tracking both Supreme Court jurisprudence and stalled congressional efforts simultaneously.

Why This Matters

Mexico's cannabis policy evolution carries implications far beyond its borders, affecting North American trade dynamics, international drug policy norms, and a potential $3-5 billion domestic market. The stakes involve multiple constituencies. For the estimated 2.5 million Mexicans who consume cannabis according to government surveys, the current legal ambiguity creates risks of arrest despite constitutional protections. Medical patients seeking cannabis therapies face access barriers due to the lack of a regulated supply chain, forcing many to rely on informal markets or cross-border purchases. Indigenous communities in states like Oaxaca and Guerrero, which have cultivated cannabis for generations, remain criminalized under federal law while awaiting promised economic opportunities from legalization. From an economic perspective, Mexico's delay has allowed Canada and U.S. states to dominate the North American cannabis market. Industry analysts estimated Mexico could generate $1.2 billion in annual tax revenue from a regulated adult-use market, funds that could address public health and security priorities. Multi-state operators (MSOs) including Khiron Life Sciences and Clever Leaves have invested in Mexican cultivation licenses anticipating regulatory clarity that has yet to materialize. The uncertainty has stalled capital deployment and left international investors watching from the sidelines. Geopolitically, Mexico's approach influences cannabis policy debates across Latin America. Colombia, Argentina, and Uruguay have all looked to Mexico's experience when crafting their own frameworks. The country's position as a signatory to international drug control treaties, including the 1961 Single Convention on Narcotic Drugs, makes its domestic reforms relevant to global prohibition regimes. Mexico's experience demonstrates how judicial activism can advance drug policy reform even when legislative bodies remain gridlocked.

Background and History: From Prohibition to Judicial Mandate

Mexico's modern cannabis prohibition dates to the 1920s, but the path toward legalization began with a 2015 Supreme Court ruling that would fundamentally reshape the constitutional landscape.

Early Prohibition Era (1920-2000)

Mexico criminalized cannabis in 1920 under the Sanitary Code, decades before the United States federal prohibition. The 1940 General Health Law codified cannabis as a prohibited substance with no recognized medical value, a classification that remained largely unchanged for 75 years. During this period, Mexico became a major cannabis producer for U.S. markets, with cultivation concentrated in the "Golden Triangle" region spanning Sinaloa, Durango, and Chihuahua. The U.S.-backed "War on Drugs" intensified enforcement beginning in the 1970s, leading to aerial eradication campaigns and militarized interdiction efforts that continue to shape security policy. A modest reform in 2009 decriminalized possession of up to 5 grams of cannabis for personal use, allowing police to confiscate the substance without criminal charges for first-time offenders. This change had limited practical impact, as possession remained administratively sanctioned and no legal supply mechanism existed.

The SMART Case and Constitutional Breakthrough (2015)

The turning point arrived on November 4, 2015, when the SCJN ruled 4-1 in favor of four members of the Mexican Society for Responsible and Tolerant Personal Use (SMART) who had sued for the right to cultivate and consume cannabis. The Court found that Articles 235, 237, 245, 247, and 248 of the General Health Law violated the constitutional right to free development of personality enshrined in Article 1 of the Mexican Constitution. Justice Arturo Zaldívar wrote in the majority opinion that while the state has legitimate interests in protecting public health, the absolute prohibition on personal cannabis use was disproportionate and unconstitutional. This single case did not immediately change the law for all Mexicans—it only granted the four plaintiffs permission to grow and consume cannabis. However, it established the legal reasoning that would cascade through subsequent rulings.

Jurisprudential Threshold and Congressional Mandate (2018-2019)

Between 2015 and 2018, the SCJN heard multiple similar cases, each time ruling that cannabis prohibition violated constitutional rights. Under Mexican law, when the Supreme Court issues five consecutive rulings on the same constitutional question, it establishes binding jurisprudential precedent (jurisprudencia) that applies to all courts nationwide. On October 31, 2018, the SCJN reached this threshold, declaring cannabis prohibition unconstitutional as a matter of settled law. The Court went further, issuing a formal declaration of unconstitutionality and ordering the Mexican Congress to reform the General Health Law within 90 days. This deadline passed without action. The Court granted multiple extensions—first to April 30, 2019, then to October 31, 2019, and finally to April 30, 2020. Each deadline came and went as the Senate and Chamber of Deputies debated competing legalization bills but failed to reach consensus.

Legislative Attempts and Failures (2020-2024)

In March 2020, the Senate approved a comprehensive cannabis legalization bill with a 82-18 vote. The legislation would have created a Mexican Cannabis Institute (Instituto Mexicano del Cannabis) to oversee licensing, permitted adults 18 and older to possess up to 28 grams and cultivate up to six plants, and established a regulated commercial market. The bill included social equity provisions prioritizing licenses for communities affected by prohibition and indigenous groups. The Chamber of Deputies, however, substantially amended the Senate version, reducing possession limits to 5 grams and imposing stricter cultivation restrictions. These changes proved unacceptable to Senate leaders. The legislative session ended in December 2020 without reconciliation. A new Congress convened in 2021, and the process restarted. Throughout 2021-2023, various legalization proposals circulated in both chambers. Key sticking points included THC potency limits (proposals ranged from 1% to 15%), the role of existing pharmaceutical companies versus new cannabis-specific businesses, taxation rates, and whether to allow foreign investment in cultivation. President Andrés Manuel López Obrador's administration offered limited public support for legalization, prioritizing other policy initiatives and expressing concerns about youth consumption. By 2024, legislative momentum had stalled completely. No legalization bill reached a floor vote in either chamber during the entire year, despite continued advocacy from civil society organizations and mounting pressure from the business community.

Judicial Expansion of Rights (2024-2026)

As Congress remained deadlocked, the SCJN continued expanding cannabis rights through individual rulings. In June 2024, the Court ruled that the constitutional right to cannabis cultivation and consumption extends to collective use in private spaces, allowing cannabis social clubs to operate legally. In January 2025, the SCJN held that prohibitions on cannabis transportation violated free movement rights when individuals were transporting quantities consistent with personal use. The September 2026 ruling on cannabis-infused foods represents the latest expansion. The Court held that the constitutional right to personal cannabis use necessarily includes the right to consume cannabis in edible form, as the method of consumption does not alter the fundamental liberty interest at stake. This decision allows individuals to legally produce and consume cannabis edibles for personal use, though commercial production and sale remain prohibited.

Key Players

Supreme Court of Justice of the Nation (SCJN)

The 11-member SCJN has served as the primary driver of cannabis reform in Mexico. Chief Justice Norma Lucía Piña Hernández has presided over the Court since January 2023, though the cannabis jurisprudence was largely established under her predecessor Arturo Zaldívar, who served from 2019-2022. Justice Zaldívar authored many of the key cannabis decisions and publicly advocated for comprehensive legalization. The Court's First Chamber, which handles constitutional rights cases, has been particularly active in cannabis litigation. The SCJN's approach reflects a broader trend of judicial activism on social issues in Mexico, similar to its rulings on same-sex marriage and abortion rights.

Mexican Congress

The bicameral Congress consists of the 128-member Senate and the 500-member Chamber of Deputies. The Senate has historically been more supportive of legalization, with the Morena party (Movement for National Regeneration) holding a majority since 2018. Senator Jesusa Rodríguez, a prominent legalization advocate, has introduced multiple reform bills and chairs the Senate's Justice Committee. In the Chamber of Deputies, Representative Juan Ramiro Robledo has led legalization efforts, though he faces stronger opposition from conservative parties including the National Action Party (PAN). The lack of presidential leadership on the issue has allowed individual legislators to avoid taking clear positions, contributing to the legislative stalemate.

Federal Commission for the Protection Against Sanitary Risks (COFEPRIS)

COFEPRIS, Mexico's equivalent to the FDA, regulates medical cannabis under the limited framework established by 2017 reforms to the General Health Law. The agency has approved cannabis-derived medications including Sativex and Epidiolex for specific medical conditions. COFEPRIS has issued approximately 600 permits for medical cannabis imports and 12 licenses for domestic cultivation of low-THC cannabis for medical research. The agency has stated it is prepared to implement a comprehensive regulatory framework once Congress enacts enabling legislation, but lacks authority to create a legal market through administrative action alone.

Civil Society and Advocacy Organizations

Multiple organizations have driven cannabis reform through litigation and advocacy. Mexico Unido Contra la Delincuencia (Mexico United Against Crime) has provided legal support for constitutional challenges and published research on the public health impacts of prohibition. Fundación Renovatio has focused on medical cannabis access and patient rights. The Collective for an Integral Cannabis Policy (Colectivo por una Política Integral hacia las Drogas) coordinates advocacy efforts across multiple civil society groups. These organizations have been instrumental in bringing the cases that established constitutional precedent and maintaining public pressure on Congress.

International Cannabis Companies

Several multinational operators have established Mexican operations anticipating legalization. Khiron Life Sciences, a Canadian company, secured cultivation licenses in 2019 and operates a medical cannabis facility in Puebla. Clever Leaves, a Colombian company with operations in Portugal and Colombia, announced plans for Mexican expansion in 2021 but has scaled back investments due to regulatory uncertainty. Canopy Growth explored Mexican partnerships in 2019-2020 but ultimately withdrew. The regulatory limbo has made Mexico a challenging market for international capital, with most companies adopting a wait-and-see approach.

Legal and Regulatory Framework

Mexico's cannabis legal framework exists in a state of constitutional contradiction, where Supreme Court rulings protect individual rights but statutory law maintains prohibition. The primary statute governing controlled substances is the General Health Law (Ley General de Salud), specifically Articles 235-248, which classify cannabis as a prohibited substance with no accepted medical use. These provisions remain on the books despite being declared unconstitutional. The Federal Penal Code criminalizes cannabis production, distribution, and sale, with penalties ranging from 10-25 years imprisonment for commercial quantities. The constitutional basis for cannabis rights derives from Article 1 of the Mexican Constitution, which protects human dignity and the free development of personality. The SCJN has interpreted this provision to encompass personal autonomy over consumption decisions that do not harm others. This reasoning parallels the Court's approach to other personal liberty issues, including reproductive rights and marriage equality. The 2017 medical cannabis reforms amended the General Health Law to remove THC from the list of prohibited substances when used for medical or scientific purposes. These changes created a narrow pathway for medical cannabis under COFEPRIS oversight, but implementation has been limited. Patients can obtain prescriptions for imported cannabis medications, but domestic production remains minimal and no dispensary system exists. The jurisprudential precedent established in 2018 theoretically allows any Mexican citizen to petition for an amparo (constitutional protection order) to cultivate and consume cannabis for personal use. However, the amparo process requires legal representation and can take months or years, creating a de facto barrier for most citizens. As of 2026, approximately 12,000 amparos related to cannabis rights have been granted, according to federal judiciary statistics. The September 2026 edibles ruling builds on the existing jurisprudence by extending constitutional protection to consumption methods beyond smoking or vaping. The Court reasoned that the constitutional right to cannabis use cannot be limited to specific delivery mechanisms, as this would arbitrarily restrict the exercise of a fundamental liberty. This logic suggests future rulings may extend protection to other cannabis products, including concentrates and topicals.

State-by-State Breakdown

While cannabis policy is primarily federal in Mexico, state and municipal governments have adopted varying approaches to enforcement and local regulation.

Mexico City (Ciudad de México)

The capital has been the most progressive jurisdiction on cannabis policy. In 2019, the Mexico City Congress passed a resolution supporting federal legalization and directing local police to deprioritize cannabis possession enforcement. The city government has hosted cannabis expos and public forums on legalization. Several cannabis social clubs operate openly in neighborhoods including Condesa and Roma, though their legal status remains uncertain. Mexico City would likely become the center of a legal cannabis industry due to its concentration of capital, consumers, and cultural acceptance.

Jalisco

The state containing Guadalajara, Mexico's second-largest city, has seen growing cannabis advocacy and business interest. The Jalisco state legislature passed a non-binding resolution in 2020 urging federal legalization. Local prosecutors have generally declined to pursue cases involving small-scale personal cultivation following the SCJN rulings. Several hemp cultivation operations have launched in rural Jalisco under agricultural permits, occupying a legal gray area.

Oaxaca

This southern state has a long history of indigenous cannabis cultivation, particularly in the Sierra Madre del Sur mountains. Indigenous communities have sought recognition of traditional cultivation rights and priority access to commercial licenses under proposed legalization frameworks. The state government has been cautious, balancing cultural recognition against concerns about cartel involvement in cannabis production. Oaxaca would likely benefit from provisions in legalization bills that prioritize indigenous and campesino participation.

Baja California

The border state has experienced spillover effects from California's legal market, with cross-border cannabis tourism and informal trade. Tijuana and Mexicali have seen proliferation of stores selling CBD products and hemp-derived goods, operating in regulatory ambiguity. State authorities have generally tolerated these businesses while awaiting federal clarity. Baja California's proximity to California creates unique market dynamics and enforcement challenges.

Sinaloa

As part of the traditional cannabis-producing Golden Triangle, Sinaloa has complex relationships with cannabis cultivation. While the state has been associated with cartel production, there is also interest in transitioning to legal cultivation. The state agricultural department has conducted studies on cannabis as a legal crop alternative for farmers. However, security concerns and cartel influence complicate legalization prospects. Any federal framework would need to address how to integrate existing cultivation regions into legal markets.

Market and Business Implications

The regulatory uncertainty has created a paradox where Mexico possesses significant market potential but lacks the legal infrastructure to realize it, frustrating investors and entrepreneurs. Market analysts have estimated Mexico's legal cannabis market could reach $2-5 billion annually within five years of comprehensive legalization, based on population size, consumption rates, and pricing models from other jurisdictions. The medical cannabis segment alone could generate $400-600 million annually, according to projections from Prohibition Partners, a cannabis market research firm. These figures assume a regulated market with licensed cultivation, manufacturing, distribution, and retail. The current legal limbo has prevented this market from developing. While individuals can legally cultivate for personal use under constitutional protection, no legal mechanism exists to sell cannabis or cannabis products. This has created a situation where constitutional rights exist without supporting commercial infrastructure. Patients who obtain medical cannabis prescriptions must import products at high cost, as domestic production remains minimal. For MSOs and international cannabis companies, Mexico represents both opportunity and risk. The country's proximity to the United States, lower labor costs, and favorable climate for outdoor cultivation make it attractive for large-scale production. However, the legislative uncertainty has made investment decisions difficult. Companies that secured early cultivation licenses have faced years of waiting without the ability to generate revenue from adult-use sales. The tax implications remain unclear. Proposed legalization bills have included excise taxes ranging from 12-30% on cannabis sales, in addition to standard value-added tax (IVA). Revenue projections depend heavily on tax structure, with higher rates potentially driving consumers to informal markets. The experience of California and other high-tax jurisdictions suggests Mexico would need to balance revenue generation against market competitiveness. Banking and financial services present additional challenges. Mexican banks have been reluctant to serve cannabis businesses due to federal prohibition, even for companies operating under medical licenses. This has forced cannabis-related businesses to operate largely in cash, creating security risks and limiting growth capital. The lack of access to traditional financing has made the sector dependent on private equity and venture capital, which has been scarce given regulatory uncertainty. Employment and labor considerations also factor into market development. A legal cannabis industry could create an estimated 75,000-150,000 jobs across cultivation, processing, retail, and ancillary services, according to studies by the Mexican Institute for Competitiveness. These jobs would be concentrated in agricultural regions and urban retail centers. Labor law questions around workplace cannabis policies and employee rights remain unresolved.

What Experts Say

Policy analysts, legal scholars, and industry observers have offered varied perspectives on Mexico's protracted legalization process and its implications. Lisa Sánchez, director of Mexico Unido Contra la Delincuencia, has described the congressional inaction as a failure of democratic governance. According to Sánchez, the Supreme Court's mandate created a constitutional obligation that Congress has simply ignored, leaving millions of Mexicans in legal limbo. She has argued that the delay perpetuates the harms of prohibition, including incarceration of low-level offenders and enrichment of criminal organizations, while denying Mexico the public health and economic benefits of regulation. Jorge Hernández Tinajero, a drug policy researcher and founding member of the Collective for an Integral Cannabis Policy, has emphasized that the judicial route to legalization, while groundbreaking, creates inequities. According to Hernández Tinajero, only Mexicans with resources to hire lawyers and navigate the amparo process can exercise their constitutional cannabis rights, while poor and marginalized communities remain subject to enforcement. He has called for Congress to enact comprehensive legislation that provides equal access to cannabis rights for all citizens. From a business perspective, Andrés Fonseca, managing director of Khiron Life Sciences Mexico, has stated that the regulatory uncertainty has made Mexico a difficult market for legitimate cannabis investment. According to Fonseca, companies have invested millions in cultivation infrastructure and licensing processes but cannot generate revenue or plan long-term strategies without clear regulations. He has noted that the delay has allowed illicit markets to continue dominating, making eventual market entry more challenging for licensed operators. Legal scholar Catalina Pérez Correa, a professor at CIDE (Centro de Investigación y Docencia Económicas), has analyzed the constitutional implications of the SCJN rulings. According to Pérez Correa, the Court's cannabis jurisprudence represents a significant expansion of personal liberty rights in Mexican constitutional law, with potential applications beyond drug policy. She has observed that the rulings place Mexico at the forefront of international human rights approaches to drug use, even as the legislative branch lags behind. International observers have also weighed in. John Walsh, director for drug policy and the Andes at the Washington Office on Latin America, has described Mexico's situation as illustrating the limitations of judicial reform without legislative follow-through. According to Walsh, while court rulings can establish rights, only comprehensive legislation can create the regulatory frameworks necessary for those rights to be meaningfully exercised. He has suggested that Mexico's experience offers lessons for other countries considering cannabis reform.

What's Next

The path forward for Mexico cannabis legalization depends on legislative action that has proven elusive, though multiple scenarios could drive progress in the coming months. The most direct path remains congressional legislation. The current legislative session runs through August 2027, providing a window for renewed legalization efforts. Several factors could catalyze action. First, the September 2026 SCJN ruling on edibles may prompt renewed judicial pressure on Congress, potentially including another formal deadline. Second, the 2024 election cycle brought new legislators who may prioritize cannabis reform. Third, growing public support for legalization—polls consistently show 60-65% of Mexicans favor some form of legal cannabis—could create political incentives for action. Key dates to watch include the opening of the spring 2027 legislative session in February, when cannabis reform bills could be introduced. Committee hearings in the Senate's Justice and Health committees would signal serious legislative consideration. Any bill would need to pass both chambers in identical form, a process that has proven difficult in previous attempts. Alternative scenarios exist if Congress continues to stall. The SCJN could issue additional rulings that further expand cannabis rights, potentially including decisions on commercial activity or interstate transportation. Some legal scholars have suggested the Court could declare the entire prohibition framework void, forcing Congress to act by creating a legal vacuum. However, the Court has historically been reluctant to take such dramatic action, preferring to give the legislative branch opportunities to fulfill its constitutional obligations. Regulatory developments at COFEPRIS could also shape the landscape. The agency has authority to expand medical cannabis access within existing statutory limits, potentially issuing more cultivation licenses or approving additional cannabis medications. While this would not address adult-use legalization, it could build regulatory capacity and normalize cannabis commerce. International factors may also influence Mexico's timeline. The United Nations Commission on Narcotic Drugs' ongoing review of cannabis scheduling under international treaties could provide political cover for domestic reform. Additionally, developments in U.S. federal cannabis policy, including potential rescheduling or banking reform, could affect Mexico's calculations about regional harmonization. For businesses and investors, the practical timeline remains uncertain. Even if Congress passes legislation in 2027, regulatory implementation would likely take 12-18 months, meaning licensed sales might not commence until 2028-2029. Companies are advised to monitor legislative developments closely while maintaining flexibility in their Mexico strategies. For patients and consumers, the immediate future involves continued reliance on constitutional protections for personal use while awaiting a legal supply chain. Advocacy organizations continue to support amparo petitions and push for legislative action. The September 2026 edibles ruling provides expanded options for personal consumption, though the lack of legal product sources remains a fundamental limitation.

Further Reading

• Supreme Court of Justice of the Nation (SCJN) cannabis jurisprudence database: https://www.scjn.gob.mx/
• General Health Law (Ley General de Salud), Articles 235-248: http://www.diputados.gob.mx/LeyesBiblio/pdf/142_190221.pdf
• COFEPRIS medical cannabis regulatory framework: https://www.gob.mx/cofepris/
• Mexico Unido Contra la Delincuencia cannabis policy research: https://www.mucd.org.mx/
• Senate cannabis legalization bill (2020 version): http://www.senado.gob.mx/
• Chamber of Deputies legislative tracking system: http://www.diputados.gob.mx/
• Mexican Constitution, Article 1 (free development of personality): http://www.diputados.gob.mx/LeyesBiblio/pdf/1_280521.pdf
• Prohibition Partners Mexico cannabis market report: https://prohibitionpartners.com/
• Washington Office on Latin America (WOLA) drug policy analysis: https://www.wola.org/program/drug-policy/
• Federal Penal Code cannabis provisions: http://www.diputados.gob.mx/LeyesBiblio/pdf/9_190221.pdf